320-OR: Cardiovascular Effectiveness of Empagliflozin in Patients with and without Cardiovascular Disease

Volume: 70
Published: Jun 1, 2021
Abstract
In the EMPA REG OUTCOME trial, empagliflozin (EMPA) reduced the risk of cardiovascular (CV) death, all-cause mortality, and hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) and established CV disease (CVD). We assessed the CV effectiveness of EMPA in real-world T2D patients with and without CVD within EMPRISE, a study on the effectiveness, safety and healthcare utilization of EMPA, based on Medicare and 2 U.S....
Paper Details
Title
320-OR: Cardiovascular Effectiveness of Empagliflozin in Patients with and without Cardiovascular Disease
Published Date
Jun 1, 2021
Journal
Volume
70
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.